Publications by authors named "Michael Liebowitz"

Claim this Profile
V
Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial.
Robert L Findling, Alain Katic, Michael Liebowitz, James Waxmonsky, Nicholas Fry

CNS Drugs· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and tolerability of nivasorexant in adults with binge-eating disorder: A randomized, Phase II proof of concept trial.
Susan L McElroy, Preciosa M Coloma, Benjamin Berger, Anna I Guerdjikova, J Mark Joyce, Michael R Liebowitz

Int J Eat Disord· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials.
Lenard A Adler, Julie Adams, Jessica Madera-McDonough, Eva Kohegyi, Mary Hobart, Michael Liebowitz

J Clin Psychopharmacol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neural circuits of anxiolytic and antidepressant molecules.
Louis Monti, Michael R Liebowitz

CNS Spectr· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study.
Mark E Schmidt, Michael R Liebowitz, Murray B Stein, Jennifer Grunfeld, Ilse Van Hove

Neuropsychopharmacology· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing dissociative symptoms following the use of esketamine nasal spray: a case report.
Sophia Pereira, Emily Brennan, Anjali Patel, Melissa Moran, Jenny Wallier, Michael R Liebowitz

Int Clin Psychopharmacol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Maggie Fedgchin, Madhukar Trivedi, Ella J Daly, Rama Melkote, Rosanne Lane, Michael Liebowitz

Int J Neuropsychopharmacol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacotherapy for social anxiety disorder: Interpersonal predictors of outcome and the mediating role of the working alliance.
Jonah N Cohen, Deborah A G Drabick, Carlos Blanco, Franklin R Schneier, Michael R Liebowitz

J Anxiety Disord· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder.
Michael R Liebowitz, Jason Careri, Kyra Blatt, Ann Draine, Junko Morita

Depress Anxiety· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The structure of vulnerabilities for social anxiety disorder.
Thomas L Rodebaugh, Cheri A Levinson, Julia K Langer, Justin W Weeks, Richard G Heimberg, Michael R Liebowitz

Psychiatry Res· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of as-needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder.
Michael R Liebowitz, Rita Hanover, Ann Draine, Rita Lemming, Jason Careri

Depress Anxiety· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Vilazodone in Generalized Social Anxiety Disorder.
Jason M Careri, Ann E Draine, Rita Hanover, Michael R Liebowitz

Prim Care Companion CNS Disord· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical presentation and pharmacotherapy response in social anxiety disorder: The effect of etiological beliefs.
Jonah N Cohen, Carrie M Potter, Deborah A G Drabick, Carlos Blanco, Franklin R Schneier, Michael R Liebowitz

Psychiatry Res· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the Straightforwardly-Worded Brief Fear of Negative Evaluation Scale for Differential Item Functioning Across Gender and Ethnicity.
Jared K Harpole, Cheri A Levinson, Carol M Woods, Thomas L Rodebaugh, Justin W Weeks, Michael Liebowitz

J Psychopathol Behav Assess· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Social Interaction Phobia Scale: Continued support for the psychometric validity of the SIPS using clinical and non-clinical samples.
Alison R Menatti, Justin W Weeks, R Nicholas Carleton, Amanda S Morrison, Richard G Heimberg, Michael R Liebowitz

J Anxiety Disord· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.
Edna B Foa, Helen Blair Simpson, David Rosenfield, Michael R Liebowitz, Shawn P Cahill

J Clin Psychiatry· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perception matters for clinical perfectionism and social anxiety.
Cheri A Levinson, Thomas L Rodebaugh, Erik A Shumaker, Andrew R Menatti, Justin W Weeks, Michael R Liebowitz

J Anxiety Disord· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of symptom dimensions on outcome for exposure and ritual prevention therapy in obsessive-compulsive disorder.
Monnica T Williams, Samantha G Farris, Eric N Turkheimer, Martin E Franklin, H Blair Simpson, Michael Liebowitz

J Anxiety Disord· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Social anxiety disorder in DSM-5.
Richard G Heimberg, Stefan G Hofmann, Michael R Liebowitz, Franklin R Schneier, Jasper A J Smits

Depress Anxiety· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the psychometric properties of two short forms of the social interaction anxiety scale and the social phobia scale.
Allura L Le Blanc, Laura C Bruce, Richard G Heimberg, Debra A Hope, Carlos Blanco, Michael R Liebowitz

Assessment· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder.
Michael R Liebowitz, Ester Salman, Humberto Nicolini, Norman Rosenthal, Rita Hanover

Am J Psychiatry· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.
David Bakish, Anjana Bose, Carl Gommoll, Changzheng Chen, Rene Nunez, Michael Liebowitz

J Psychiatry Neurosci· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
Helen Blair Simpson, Edna B Foa, Michael R Liebowitz, Jonathan D Huppert, Shawn Cahill

JAMA Psychiatry· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder.
Edna B Foa, Helen Blair Simpson, Michael R Liebowitz, Mark B Powers, David Rosenfield

J Clin Psychiatry· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder.
Michael R Liebowitz, Karen A Tourian, Eunhee Hwang, Linda Mele,

BMC Psychiatry· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis